Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04958109 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test
A Phase 1 study of Metabolic Diseases, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT04958109: Completed Phase 1 study of Metabolic Diseases, sponsored by Massachusetts General Hospital.
NCT04958109 is a Phase 1 study of Metabolic Diseases that has completed, run by Massachusetts General Hospital. The registered enrollment target is 16 participants, below the 197-participant average among 12 other Metabolic Diseases trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04958109, a Phase 1 study of Metabolic Diseases, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to understand how exogenous kisspeptin affects metabolism by evaluating responses to an oral glucose tolerance test
Primary Outcome
Change in Oral glucose Sensitivity Index between kisspeptin and placebo arms in oral glucose tolerance test
Conditions Studied
Interventions
- DRUG Placebo
- DIAGNOSTIC_TEST Oral Glucose Tolerance Test
- DRUG Kisspeptin
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-10-28 |
| Est. Completion | 2022-10-31 |
| Phase | Phase 1 |
What the finished NCT04958109 record still lists
NCT04958109 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 197-participant average among 12 other Metabolic Diseases trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Metabolic Diseases appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04958109 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04958109 about?
NCT04958109 is a clinical study titled "Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test". The goal of this study is to understand how exogenous kisspeptin affects metabolism by evaluating responses to an oral glucose tolerance test
What is the current status of trial NCT04958109?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-10-28. Estimated completion is 2022-10-31.
What conditions does trial NCT04958109 study?
This clinical trial studies the following conditions: Metabolic Diseases.
What interventions are being tested in trial NCT04958109?
The interventions under investigation include: Placebo (DRUG), Oral Glucose Tolerance Test (DIAGNOSTIC_TEST), Kisspeptin (DRUG).
Who is sponsoring clinical trial NCT04958109?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04958109 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolic Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04958109's enrollment target sits among peer trials
16 12th of 12 the lowest of 12 other Metabolic Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metabolic Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
COMPLETED · Phase 1
-
Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc
RECRUITING · NA
-
Effects of HIIT vs. TRE on Type 2 Diabetes Risk
RECRUITING · NA
-
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
RECRUITING · Phase 4
-
The Effect of Processing on Food Reward
RECRUITING · NA
-
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI